Agilent Q2 Earnings Beat Estimates, Revenues Up Y/Y, Shares Rise

Agilent Technologies (A) reported fiscal Q2 2025 earnings of $1.31 per share, exceeding estimates by 3.97% and growing 7.4% year-over-year, while revenues of $1.67 billion beat estimates by 2.64%, representing a 6% increase. The growth was fueled by strong performance in Pharmaceuticals and increased demand across various markets, leading to a 4.71% gain in after-hours trading. The company revised its fiscal year 2025 revenue guidance upward to $6.73-$6.81 billion, reaffirming its EPS guidance of $5.54-$5.61.

Analysis

Agilent Technologies reported robust second-quarter fiscal 2025 results, with earnings of $1.31 per share exceeding Zacks Consensus Estimates by 3.97% and increasing 7.4% year-over-year. Revenues reached $1.67 billion, also surpassing consensus by 2.64% and growing 6% on a reported basis (5.3% core) year-over-year, primarily driven by sustained improvements in Pharmaceuticals and heightened demand across Diagnostics and Clinical, Food, and Environmental and Forensics markets, which prompted a 4.71% rise in its share price in after-hours trading. The Life Sciences and Diagnostics Markets Group (LDG) and the Agilent CrossLab Group (ACG) were key growth drivers, with reported revenue increases of 8% to $654 million and 7% to $713 million, respectively, buoyed by strong LC/LCMS instrument sales and double-digit growth in automation and consumables. Conversely, the Applied Markets Group (AMG) experienced a 1% revenue decline to $301 million, attributed to timing-related issues in gas chromatography and challenges in the Chinese market. While Agilent maintained its overall non-GAAP operating margin at 25.1%, aligning with the prior year, all three segments saw gross margin contractions: LDG to 52.8% (-230 bps), ACG to 55.5% (-110 bps), and AMG to 53.5% (-70 bps). However, operating expenses as a percentage of revenue showed improvement, with R&D falling to 6.5% and SG&A to 22.4%. The company demonstrated strong cash generation with operating cash flow significantly increasing to $652 million. Looking forward, Agilent raised its full-year fiscal 2025 revenue guidance to $6.73-$6.81 billion, up from $6.68-$6.76 billion, and reaffirmed its non-GAAP EPS guidance at $5.54-$5.61, projecting Q3 fiscal 2025 revenues between $1.645-$1.675 billion and non-GAAP EPS of $1.35-$1.37.

Key Decisions for Investors

• Consider the strong Q2 earnings, revenue beat, and upwardly revised FY25 revenue guidance as positive indicators for Agilent's financial health and growth trajectory.
• Monitor the performance of the Applied Markets Group, particularly its challenges in China and timing-related declines, as a potential drag on overall results.
• Evaluate the impact of gross margin contractions across all segments on future profitability, despite stable overall operating margins and controlled operating expenses.
• Note that the reaffirmed FY25 EPS guidance, despite higher revenue projections, may suggest ongoing cost pressures or strategic investments impacting near-term margin expansion.